Related Experiment Video

Updated: May 2, 2026

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

11.3K

Chromium picolinate inhibits cholesterol-induced stimulation of platelet aggregation in hypercholesterolemic rats

A A Seif1

  • 1Physiology Department, Faculty of Medicine, Ain Shams University, Abbassyia District of Cairo Governorate, on Ahmed Lotfy Al-Sayed Street, Cairo, Egypt, ansamseif@yahoo.com.

Irish Journal of Medical Science
|March 18, 2014
PubMed

Insights

Chromium supplementation normalized high-fat diet-induced increases in plasma lipids and platelet aggregation in rats. This suggests chromium may help manage cardiovascular risk factors associated with hypercholesterolemia.

Area of Science:

  • Biochemistry
  • Cardiovascular Research
  • Nutritional Science

Background:

  • Hypercholesterolemia is linked to increased myocardial infarction risk via enhanced platelet aggregation.
  • Chromium supplementation is known to potentially reduce plasma lipid levels.

Purpose of the Study:

  • To investigate the inhibitory effect of chromium on platelet aggregation in hypercholesterolemic conditions.
  • To assess chromium's impact on lipid profiles and platelet activity.

Main Methods:

  • Albino rats were divided into control, chromium-supplemented, high-fat diet, and high-fat diet with chromium groups.
  • Evaluated adenosine diphosphate and collagen-induced platelet aggregation.
  • Measured plasma lipids (cholesterol, triglycerides) and biomarkers (apolipoproteins, thromboxane B2).

Main Results:

  • High-fat diet significantly elevated plasma lipids and platelet aggregation.
  • Chromium supplementation normalized these elevations in hypercholesterolemic rats.
  • Chromium had no significant effect on lipid or platelet activity in normolipemic rats.

Conclusions:

  • Chromium supplementation improves lipid profiles in hypercholesterolemic rats.
  • It effectively reduces platelet hyperaggregability to normal levels.
  • The primary mechanism appears to be a reduction in plasma cholesterol.
Abstract

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K
Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
2.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K